-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Market Analysis] Pharmaceutical equipment is the upstream of the pharmaceutical industry, and the market space is huge
.
Data show that the current global pharmaceutical equipment industry scale has exceeded 500 billion yuan, and it will exceed 700 billion yuan in 2025
.
Among them, the Chinese market is nearly 100 billion yuan, and it is expected to reach 200 billion yuan by 2025
.
It is worth mentioning that although the pharmaceutical machine market has promising prospects, the industry is also facing challenges from fierce market competition and product homogeneity
.
So, how can pharmaceutical machine companies open the ceiling of the pharmaceutical equipment industry? Pharmaceutical equipment (photo source: Pharmaceutical Network) First, extend upstream
.
In recent years, innovative drugs including antibody drugs, cell therapy, and gene drugs have flourished, bringing new development opportunities to the upstream equipment and consumables industries
.
According to Frost & Sullivan, China's biological drug market space will increase from 312 billion yuan in 2019 to 1,303 billion yuan in 2030
.
According to estimates by ResearchandMarkets and other institutions, China's biopharmaceutical equipment + consumables market will be about 25 billion yuan in 2020, of which equipment will be about 10.
2 billion yuan and consumables will be about 13.
5 billion yuan.
The expected growth rates from 2020 to 2025 are 17% and 20%, respectively
.
There is a lot of room for growth of consumables in the future
.
The industry believes that the horizontal expansion of pharmaceutical machine companies from pharmaceutical equipment to upstream consumables will be a major means to open the industry ceiling
.
At present, many domestic pharmaceutical machine giants have plans to extend upstream or in-depth layout
.
For example, Tofflon recently disclosed its plan to issue A shares to specific objects in 2022, showing that it plans to raise no more than 3.
2 billion yuan, which will be used to enrich the front-end product line (DS) of biopharmaceuticals and cell gene therapy, and the injection production line (DP).
Innovation upgrade and production expansion
.
After the project is completed, an integrated industrial ecology of CGT pharmaceutical equipment, instruments and consumables will be built
.
In recent years, Chutian Technology has closely followed the development of the times and actively deployed fillers, auxiliary materials, packaging materials, etc.
in the field of consumables.
Benchmarking Sartorius, it has established a holding subsidiary, Chutian Si Youte (SUT), which specializes in the deployment of disposable technology products such as biological reactions.
Disposable bags, liquid dispensing bags, liquid storage bags, breathing bags and their membranes
.
Recently, the company also announced that it plans to invest 25.
5 million yuan to jointly establish a company, Chutian Siweikang, in Ningxiang City, Changsha, Hunan Province, with the main business of providing equipment, consumables and accessories related to cell processing systems
.
In addition, Xinhua Medical, whose main business includes pharmaceutical equipment, also recently stated that it will intervene in some biological raw materials in the future to make the layout of equipment and consumable solutions
.
Second, accelerate domestic substitution and deploy export business
.
In 2020, in the case of delayed delivery of imported medicine machines, many domestic medicine machines won the opportunity to accelerate the process of domestic substitution, and domestic medicine machine companies have continuously strengthened their research and development efforts, and their products have gradually won domestic and foreign customers.
Recognition, driving the rapid growth of the export business of enterprises
.
Due to higher technical barriers and large market demand, the gross profit margin in overseas markets is high, which also makes more domestic pharmaceutical machine companies excited, and strengthens their determination to increase their size in the international market
.
For example, Chutian Technology plans to establish subsidiary companies in important international markets and expand the market scope to the world with the help of ROMACO's international market channel resources
.
It is understood that, excluding Romaco, the company plans to maintain an annual increase of 10%-20% in export business.
It is planned that by around 2025, export business revenue will account for 40%-50% of total revenue
.
Canaan Technology, which specializes in the production of solid preparation pharmaceutical equipment in China, also mentioned that there are three main aspects to predict the future growth of the pharmaceutical equipment industry, one of which is that the high-end market in the international market will usher in more opportunities for product exports
.
The 2020 annual report shows that the company's overseas performance in 2020 increased by more than 80% year-on-year
.
Guosheng Securities believes that domestic pharmaceutical equipment companies are accelerating their internationalization strategy, setting up subsidiaries overseas through "acquisition + self-construction" and other methods to increase their international layout and open up the growth ceiling
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
.
Data show that the current global pharmaceutical equipment industry scale has exceeded 500 billion yuan, and it will exceed 700 billion yuan in 2025
.
Among them, the Chinese market is nearly 100 billion yuan, and it is expected to reach 200 billion yuan by 2025
.
It is worth mentioning that although the pharmaceutical machine market has promising prospects, the industry is also facing challenges from fierce market competition and product homogeneity
.
So, how can pharmaceutical machine companies open the ceiling of the pharmaceutical equipment industry? Pharmaceutical equipment (photo source: Pharmaceutical Network) First, extend upstream
.
In recent years, innovative drugs including antibody drugs, cell therapy, and gene drugs have flourished, bringing new development opportunities to the upstream equipment and consumables industries
.
According to Frost & Sullivan, China's biological drug market space will increase from 312 billion yuan in 2019 to 1,303 billion yuan in 2030
.
According to estimates by ResearchandMarkets and other institutions, China's biopharmaceutical equipment + consumables market will be about 25 billion yuan in 2020, of which equipment will be about 10.
2 billion yuan and consumables will be about 13.
5 billion yuan.
The expected growth rates from 2020 to 2025 are 17% and 20%, respectively
.
There is a lot of room for growth of consumables in the future
.
The industry believes that the horizontal expansion of pharmaceutical machine companies from pharmaceutical equipment to upstream consumables will be a major means to open the industry ceiling
.
At present, many domestic pharmaceutical machine giants have plans to extend upstream or in-depth layout
.
For example, Tofflon recently disclosed its plan to issue A shares to specific objects in 2022, showing that it plans to raise no more than 3.
2 billion yuan, which will be used to enrich the front-end product line (DS) of biopharmaceuticals and cell gene therapy, and the injection production line (DP).
Innovation upgrade and production expansion
.
After the project is completed, an integrated industrial ecology of CGT pharmaceutical equipment, instruments and consumables will be built
.
In recent years, Chutian Technology has closely followed the development of the times and actively deployed fillers, auxiliary materials, packaging materials, etc.
in the field of consumables.
Benchmarking Sartorius, it has established a holding subsidiary, Chutian Si Youte (SUT), which specializes in the deployment of disposable technology products such as biological reactions.
Disposable bags, liquid dispensing bags, liquid storage bags, breathing bags and their membranes
.
Recently, the company also announced that it plans to invest 25.
5 million yuan to jointly establish a company, Chutian Siweikang, in Ningxiang City, Changsha, Hunan Province, with the main business of providing equipment, consumables and accessories related to cell processing systems
.
In addition, Xinhua Medical, whose main business includes pharmaceutical equipment, also recently stated that it will intervene in some biological raw materials in the future to make the layout of equipment and consumable solutions
.
Second, accelerate domestic substitution and deploy export business
.
In 2020, in the case of delayed delivery of imported medicine machines, many domestic medicine machines won the opportunity to accelerate the process of domestic substitution, and domestic medicine machine companies have continuously strengthened their research and development efforts, and their products have gradually won domestic and foreign customers.
Recognition, driving the rapid growth of the export business of enterprises
.
Due to higher technical barriers and large market demand, the gross profit margin in overseas markets is high, which also makes more domestic pharmaceutical machine companies excited, and strengthens their determination to increase their size in the international market
.
For example, Chutian Technology plans to establish subsidiary companies in important international markets and expand the market scope to the world with the help of ROMACO's international market channel resources
.
It is understood that, excluding Romaco, the company plans to maintain an annual increase of 10%-20% in export business.
It is planned that by around 2025, export business revenue will account for 40%-50% of total revenue
.
Canaan Technology, which specializes in the production of solid preparation pharmaceutical equipment in China, also mentioned that there are three main aspects to predict the future growth of the pharmaceutical equipment industry, one of which is that the high-end market in the international market will usher in more opportunities for product exports
.
The 2020 annual report shows that the company's overseas performance in 2020 increased by more than 80% year-on-year
.
Guosheng Securities believes that domestic pharmaceutical equipment companies are accelerating their internationalization strategy, setting up subsidiaries overseas through "acquisition + self-construction" and other methods to increase their international layout and open up the growth ceiling
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
